You can buy or sell APLS and other stocks, options, ETFs, and crypto commission-free!
Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. Read More It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Crestwood, KY.
52 Week High
52 Week Low
Yahoo FinanceMay 13
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)
WALTHAM Mass. and CRESTWOOD, Ky., May 13, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on May 7, 2019, the Compensation Committee of the Board of Directors approved the grant of equity awards to two new employees with a grant date of May 8, 2019, as an equity inducement award outside of the Company's 2017 Stock...
Yahoo FinanceMay 9
Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the future holds and how market participants will react to the bountiful news that floods in each day. Hedge funds underperform because they are hedged. The Standard and Poor’s 500 Index returned appr...
Yahoo FinanceMay 8
Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results
Resumed Dosing in Phase 3 Geographic Atrophy Program Announced Innovative Collaboration & Financing with SFJ Pharmaceuticals® Cash Position of $288.2 Million at Quarter-End WALTHAM Mass. and CRESTWOOD, Ky., May 08, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced its first quarter 2019 financial results and bu...
-$0.67 per share
-$0.87 per share